导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.28% | 3027/4773 |
| 近一周 | -1.27% | 1926/5465 |
| 近一月 | -1.13% | 1043/5421 |
| 近一季 | 0.41% | 921/5231 |
| 近半年 | -0.23% | 1440/4920 |
| 近一年 | 1.17% | 2552/4394 |
| 近两年 | 35.80% | 2078/2954 |
| 近三年 | 22.99% | 1374/2253 |
| 成立以来 | 35.21% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.05% 4015/4961 |
6.66% 2806/5312 |
- - |
- - |
| 2025 | 16.01% 2496/4813 |
-0.21% 2105/3635 |
2.99% 1214/4076 |
10.52% 3282/4524 |
2.13% 1073/4813 |
| 2024 | 16.29% 829/3463 |
3.56% 544/2808 |
-0.57% 788/3014 |
16.31% 1485/3129 |
-2.91% 2204/3463 |
| 2023 | -7.49% 923/2656 |
1.09% 1646/2280 |
-4.06% 1032/2385 |
1.97% 265/2515 |
-6.45% 1782/2655 |
| 2022 | -16.53% 490/2207 |
-10.94% 460/1919 |
6.51% 678/2016 |
-12.73% 770/2113 |
0.82% 1445/2208 |
| 2021 | -2.91% 877/1822 |
-1.80% 543/1255 |
2.49% 1003/1330 |
-5.61% 835/1466 |
2.20% 661/1822 |
| 2020 | 29.75% 530/1250 |
-10.96% 810/1028 |
11.90% 712/1067 |
15.79% 194/1164 |
12.46% 463/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 东财上证50ETF发起式联接C VS. 长安沪深300非周期A(740101) |